Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
A Mayo Clinic-sponsored clinical trial (HALT) is evaluating strategies to manage hypertension and prevent cardiovascular adverse events in p…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Spanish Registry of Patients With IgM Monoclonal Gammopathies
A Spanish registry study updating IgM monoclonal gammopathies is recruiting, focusing on patients with Waldenström macroglobulinemia.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia [Phase 1, Phase 2]
A Phase 1/2 clinical trial of ABBV-383 for relapsed or refractory Waldenström macroglobulinemia is listed and currently not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A Dana-Farber Cancer Institute-led clinical study recruiting to investigate molecular progression and clinical outcomes in MGUS, smoldering …
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
A retrospective-prospective Italian study evaluating real-world use and outcomes of zanubrutinib (Brukinsa) in Waldenström's macroglobulinem…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia [Phase 2]
A Phase 2 clinical trial is investigating Sonrotoclax alone and in combination with Zanubrutinib in adults with Waldenström macroglobulinemi…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia [Phase 4]
This Phase 4 study is recruiting to evaluate the efficacy and safety of zanubrutinib in treatment-naive Chinese adults with Waldenström macr…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia [Phase 2]
Phase 2 study evaluating safety and efficacy of pacritinib in relapsed or refractory Waldenström macroglobulinemia; the trial is currently r…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy [Phase 2]
Phase 2 clinical trial update for ACALA-R in predominantly demyelinating IgM-mediated neuropathy; the study involves IgM monoclonal gammopat…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study
A single-center cohort study is assessing biomarkers of cardiovascular complications in patients treated with second-generation BTK inhibito…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia [Phase 2]
This clinical trial update describes a Phase II study evaluating zanubrutinib in combination with four cycles of a CD20 monoclonal antibody …
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy of venetoclax in combination with rituximab for Waldenström macroglobulinemia. The study…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia [Phase 2]
Phase 2 clinical trial evaluating the combination of zanubrutinib and BGB-11417 in patients previously treated for Waldenström macroglobulin…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease
This clinical trial update describes planned prognostic analyses on a validation series of Waldenström macroglobulinemia patients and notes …
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Watch and Wait or Worry and Wait in Indolent Lymphoma
An ongoing clinical trial at Seoul National University Hospital is evaluating watchful waiting versus proactive worry-and-wait strategies in…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) [Phase 2]
A Phase 2 clinical trial evaluating a triplet regimen of pirtobrutinib, venetoclax, and rituximab in Waldenström macroglobulinemia and lymph…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Q702 for the Treatment of Patients With Hematologic Malignancies [Phase 1]
This entry notes a Phase 1 clinical trial (Q702) for hematologic malignancies led by Mayo Clinic, currently recruiting and including histioc…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…